The document discusses the Memory Guard program and Alzheimer's disease. It describes how Alzheimer's disease affects areas of the brain responsible for memory, including the hippocampus and temporal lobes. Damage to these areas causes memory loss and inability to form new memories. The document also lists some FDA-approved medications used to treat Alzheimer's, including Donepezil, Rivastigmine, Galantamine, and Memantine. These drugs aim to boost neurotransmitters and may help with memory, speech, and behavioral issues, but their effectiveness is limited.